BCAB - BioAtla, Inc.

0.2667
-0.023   -8.774%

Share volume: 373,222
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$0.29
-0.02
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 12%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.82%
1 Month
-13.97%
3 Months
-49.83%
6 Months
-86.67%
1 Year
-92.53%
2 Year
-92.29%
Key data
Stock price
$0.27
P/E Ratio 
0.00
DAY RANGE
$0.26 - $0.31
EPS 
-$1.44
52 WEEK RANGE
$0.24 - $3.53
52 WEEK CHANGE
-$91.79
MARKET CAP 
28.582 M
YIELD 
N/A
SHARES OUTSTANDING 
48.336 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$610,759
AVERAGE 30 VOLUME 
$616,161
Company detail
CEO: Jay M. Short
Region: US
Website: bioatla.com
Employees: 60
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate.

Recent news
loading